MX2016015248A - Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. - Google Patents

Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Info

Publication number
MX2016015248A
MX2016015248A MX2016015248A MX2016015248A MX2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A
Authority
MX
Mexico
Prior art keywords
muscular atrophy
spinal muscular
pyrazin
imidazo
treating spinal
Prior art date
Application number
MX2016015248A
Other languages
English (en)
Inventor
Pinard Emmanuel
Ratni Hasane
Green Luke
Williamson Patrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015248A publication Critical patent/MX2016015248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) en donde A, X1, X2, R1, R2, R3, R4 y R5 son como se describe en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de la atrofia muscular espinal.
MX2016015248A 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. MX2016015248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173935 2014-06-25
PCT/EP2015/063894 WO2015197503A1 (en) 2014-06-25 2015-06-22 Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
MX2016015248A true MX2016015248A (es) 2017-02-23

Family

ID=50980240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015248A MX2016015248A (es) 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Country Status (10)

Country Link
US (1) US9975900B2 (es)
EP (1) EP3160967B1 (es)
JP (1) JP6675334B2 (es)
KR (1) KR102565544B1 (es)
CN (1) CN106459067B (es)
BR (1) BR112016026951B1 (es)
CA (1) CA2952895C (es)
MX (1) MX2016015248A (es)
RU (1) RU2725979C2 (es)
WO (1) WO2015197503A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6689197B2 (ja) 2013-08-19 2020-04-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スクリーニング方法
EP3848035A1 (en) 2015-12-10 2021-07-14 PTC Therapeutics, Inc. 1,4-disubstituted pyridazine compounds for treating huntington's disease
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
WO2019099578A1 (en) 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Use of imidazopyrimidine for modulating human immune response
KR20200088397A (ko) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
WO2019191092A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7421507B2 (ja) 2018-06-27 2024-01-24 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物
JP7427252B2 (ja) 2018-06-27 2024-02-05 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
US20220089592A1 (en) * 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
CA3182912A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
EP4366834A1 (en) * 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
WO2023102231A1 (en) * 2021-12-03 2023-06-08 Rgenta Therapeutics, Inc. 5-pyrimidinecarboxamide derivatives and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
EP2167491A1 (en) * 2007-06-08 2010-03-31 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
EP2651944B1 (en) * 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN104244944B (zh) * 2011-12-30 2018-06-08 Ptc医疗公司 用于治疗脊髓性肌萎缩症的化合物
US9193723B2 (en) * 2012-05-11 2015-11-24 Abbvie Inc. NAMPT inhibitors
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP2016500073A (ja) * 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
US20160145270A1 (en) 2013-06-25 2016-05-26 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy

Also Published As

Publication number Publication date
WO2015197503A1 (en) 2015-12-30
BR112016026951B1 (pt) 2022-09-20
JP2017520570A (ja) 2017-07-27
KR20170018076A (ko) 2017-02-15
JP6675334B2 (ja) 2020-04-01
RU2725979C2 (ru) 2020-07-08
CA2952895C (en) 2023-09-26
RU2017102014A (ru) 2018-07-27
CN106459067B (zh) 2019-05-31
EP3160967B1 (en) 2019-05-08
CA2952895A1 (en) 2015-12-30
US20170197969A1 (en) 2017-07-13
US9975900B2 (en) 2018-05-22
KR102565544B1 (ko) 2023-08-10
CN106459067A (zh) 2017-02-22
RU2017102014A3 (es) 2019-01-22
BR112016026951A2 (es) 2017-08-15
EP3160967A1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX363456B (es) Compuestos para tratar atrofia muscular espinal.
PH12020551762A1 (en) Peptide macrocycles against acinetobacter baumannii
PH12018500065A1 (en) Oxysterols and methods of use thereof
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
AU2018253590A1 (en) Imidazopyridazine compounds
IN2014DN06869A (es)
MX340574B (es) Imidazo pirazinas.
GB201209587D0 (en) Therapeutic compounds
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
SA520412155B1 (ar) مشتقات إيميدازوبيريدين واستخدامها كدواء
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.

Legal Events

Date Code Title Description
FG Grant or registration